Lead, Blood (Venous)
Ordering Recommendation

Recommended for routine testing for lead exposure. For occupational exposure, consider Lead, Industrial Exposure Panel, Adults (0025016).

Quantitative Inductively Coupled Plasma-Mass Spectrometry
1-3 days
New York DOH Approval Status
This test is New York DOH approved.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Royal blue (K2EDTA or Na2EDTA) or tan (K2EDTA). 
Specimen Preparation
Transport 7 mL whole blood (royal blue). (Min: 0.5 mL) OR Transport 3 mL whole blood (tan). (Min: 0.5 mL) 
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. 
Unacceptable Conditions
Serum. Specimens collected in tubes other than Royal Blue (K2EDTA or Na2EDTA) or tan (K2EDTA). Heparinized or clotted specimens. Capillary pediatric EDTA collection tubes, refer to Lead, Blood (Capillary) 0020745. 
Trace Elements requisition form may be required (ARUP form #32990). 
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
0.0-4.9 µg/dL
Interpretive Data
Elevated results may be due to skin or collection-related contamination, including the use of a noncertified lead-free tube. If contamination concerns exist due to elevated levels of blood lead, confirmation with a second specimen collected in a certified lead-free tube is recommended.

Information sources for reference intervals and interpretive comments include the "CDC Response to the 2012 Advisory Committee on Childhood Lead Poisoning Prevention Report" and the "Recommendations for Medical Management of Adult Lead Exposure, Environmental Health Perspectives, 2007." Thresholds and time intervals for retesting, medical evaluation, and response vary by state and regulatory body. Contact your State Department of Health and/or applicable regulatory agency for specific guidance on medical management recommendations.

All ages5-9.9 µg/dLAdverse health effects are possible, particularly in children under 6 years of age and pregnant women. Discuss health risks associated with continued lead exposure. For children and women who are or may become pregnant, reduce lead exposure.
All ages10-19.9 µg/dLReduced lead exposure and increased biological monitoring are recommended.
All ages20-69.9 µg/dLRemoval from lead exposure and prompt medical evaluation are recommended. Consider chelation therapy when concentrations exceed 50 µg/dL and symptoms of lead toxicity are present.
Less than 19 years of ageGreater than 44.9 µg/dLCritical. Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.
Greater than 19 years of ageGreater than 69.9 µg/dLCritical. Immediate medical evaluation is recommended. Consider chelation therapy when symptoms of lead toxicity are present.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
View Hotline History
Component Test Code*Component Chart NameLOINC
0020098Lead, Blood (Venous)77307-7
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • BLL
  • Lead (Adult)
  • Pb
  • Pb, Blood
  • Pb, Whole Blood
  • Venous blood level